{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:59:13Z","timestamp":1785488353824,"version":"3.56.0"},"reference-count":7,"publisher":"Royal College of Psychiatrists","issue":"2","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1192\/bjp.2026.10572","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:53:51Z","timestamp":1772448831000},"page":"244-244","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["Optimising clozapine use through expert consensus: commentary, Wagner & Hasan"],"prefix":"10.1192","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7147-6167","authenticated-orcid":false,"given":"Elias","family":"Wagner","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p14d497","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Augsburg"},{"name":"University of Augsburg, BKH Augsburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkomiet","family":"Hasan","sequence":"additional","affiliation":[{"name":"University of Augsburg, BKH Augsburg"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"S0007125026105728_ref5","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21335"},{"key":"S0007125026105728_ref6","volume-title":"FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia","year":"2026"},{"key":"S0007125026105728_ref4","doi-asserted-by":"publisher","DOI":"10.1177\/02698811251319458"},{"key":"S0007125026105728_ref3","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001987"},{"key":"S0007125026105728_ref1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2025.10430"},{"key":"S0007125026105728_ref2","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2024.1816"},{"key":"S0007125026105728_ref7","volume-title":"AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia","year":"2024"}],"container-title":["The British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125026105728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:21:06Z","timestamp":1785486066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125026105728\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0007125026105728"],"URL":"https:\/\/doi.org\/10.1192\/bjp.2026.10572","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"\u00a9 The Author(s), 2026. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}